Haemonetics is a medical technology company that develops and sells products for blood collection, processing, and management. The company operates three primary segments: Plasma, Hospital, and Blood Center. Haemonetics utilizes a razor-and-blade business model, placing capital equipment at customer sites to drive recurring revenue from single-use disposables. The Plasma segment provides the NexSys PCS device and consumables used by biopharmaceutical collectors to extract source plasma. Haemonetics integrates proprietary software and yield-enhancing technologies, such as Persona and Persona PLUS, to improve donor yields for its customers. The Hospital segment includes Interventional Technologies and Blood Management Technologies. Interventional products feature the VASCADE line of vascular closure devices used to seal access sites after cardiovascular procedures. Blood management offerings include the TEG 6s hemostasis analyzer, which assesses patient coagulation during surgery or trauma. The Blood Center segment provides apheresis systems for collecting blood components like platelets and plasma. Haemonetics’ strategy focuses on expanding its installed hardware base and leveraging long-term technology agreements to secure recurring consumable sales. The company is currently prioritizing growth in plasma and hospital diagnostics while narrowing its blood center operations to focus on plasma and platelet apheresis.